Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy.

Journal of Crohn's & colitis·2026
Same author

The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study.

Inflammatory bowel diseases·2026
Same author

Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis.

Inflammatory bowel diseases·2026
Same author

Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis.

Journal of Crohn's & colitis·2026
Same author

Microbiome-Directed Therapy for Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Placebo-Controlled Trial of Multistrain Probiotic Supplementation.

The American journal of gastroenterology·2026
Same author

Fecal Calprotectin as a Biomarker for Disease Activity in Microscopic Colitis.

Journal of clinical gastroenterology·2026
Same journal

Patients with Crohn's disease achieving transmural healing experience superior long-term outcomes compared with those with endoscopic or radiologic healing alone.

Inflammatory bowel diseases·2026
Same journal

Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.

Inflammatory bowel diseases·2026
Same journal

Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control study.

Inflammatory bowel diseases·2026
Same journal

Pediatric bowel-wall thickness cutoffs: calibration before implementation.

Inflammatory bowel diseases·2026
Same journal

Trained immunity: Breaking a dogma and a missing opportunity in IBD?

Inflammatory bowel diseases·2026
Same journal

Response to the letter to the editor: "pediatric bowel-wall thickness cutoffs: calibration before implementation".

Inflammatory bowel diseases·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Clostridium difficile and inflammatory bowel disease.

Mazen Issa1, Ashwin N Ananthakrishnan, David G Binion

  • 1Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.

Inflammatory Bowel Diseases
|May 20, 2008
PubMed
Summary
This summary is machine-generated.

Clostridium difficile infections are increasing in inflammatory bowel disease (IBD) patients, leading to higher hospitalization and colectomy rates. Early identification and targeted antibiotic treatment are crucial for managing this complication in IBD.

More Related Videos

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Related Experiment Videos

Last Updated: Jul 5, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Clostridium difficile colitis incidence has doubled in North America over five years.
  • Inflammatory bowel disease (IBD) patients face increased C. difficile infection (CDI) incidence and severity.
  • IBD patients with CDI experience higher morbidity and mortality.

Purpose of the Study:

  • To review current knowledge on C. difficile infections in IBD patients.
  • To highlight unique clinical scenarios, diagnostic challenges, and treatment strategies.
  • To emphasize the importance of vigilant identification and management of CDI in IBD.

Main Methods:

  • Review of current literature and institutional data.
  • Analysis of epidemiological trends in CDI among IBD patients.
  • Summary of diagnostic algorithms and treatment approaches.

Main Results:

  • Over half of C. difficile-infected IBD patients require hospitalization; colectomy rates approach 20%.
  • IBD patients often contract C. difficile as outpatients, with prior colitis being a major risk factor.
  • Metronidazole efficacy is decreased, necessitating oral vancomycin for hospitalized patients.

Conclusions:

  • C. difficile colitis can mimic or precipitate IBD flares, requiring careful diagnosis and management.
  • IBD patients are susceptible to C. difficile enteritis and pouch infections.
  • Prompt and appropriate antibiotic therapy is essential to prevent deterioration in IBD patients with CDI.